BioVie Earnings Call Transcripts
Fiscal Year 2026
-
The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.
-
Bezisterim is advancing in phase II trials for Parkinson's and long COVID, with key data readouts expected in Q2 and late summer 2024. BIV201 for ascites is preparing for phase III after strong phase II results. Strategic focus is on Parkinson's, with long COVID as a potential priority if results and FDA guidance are favorable.
Fiscal Year 2025
-
The meeting established a quorum, elected six directors for a one-year term, ratified EisnerAmper, LLP as auditor for 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan. All proposals passed with strong majority support.
-
Multiple clinical trials are progressing, with key data readouts for Parkinson's, Long COVID, and ascites expected by mid-2026. Lead drug bezisterim targets TNF-alpha and shows promise in neurodegenerative and inflammatory conditions, while financial runway extends through 2026.
-
A quorum was established with nearly all shares represented. Shareholders approved both the reverse stock split proposal and the adjournment authority, with over 79% and 81% support, respectively.
-
Bezisterim, an oral anti-inflammatory targeting the ERK/NF-kappa B pathway, is being evaluated in the Sunrise PD phase II trial for early Parkinson's. The study uses both home-based and traditional assessments, aiming to demonstrate disease modification and improved motor and non-motor symptoms.
Fiscal Year 2024
-
The meeting confirmed a quorum and approved all proposals, including director elections, auditor ratification, executive compensation, and an increase in authorized shares for the equity incentive plan, each with over 92% approval among shares represented.